Submit Manuscript Now
Current issue Archive Authors Profile
Research Articles Issue 1 · 2016 · pp. 139–146 · Issue page

NON-MUSCLE INVASIVE BLADDER CANCER RECURRENCE RISK FACTORS

OC
Octavian Dragoescu1
AN
Andrei Drocas2
GE
George MITROI3
CO
Cosmin MITITELU4
AL
Alice GĂMAN5
AN
Anca UNGUREANU6
PA
Paul TOMESCU7
1 Department of Urology, Faculty of Medicine, University of Medicine and Pharmacy Craiova
2 Department of Urology, Faculty of Medicine, University of Medicine and Pharmacy Craiova
3 Department of Urology, Faculty of Medicine, University of Medicine and Pharmacy Craiova
4 Department of Urology, Faculty of Medicine, University of Medicine and Pharmacy Craiova
5 Department of Bacteriology-Virusology- Parasitology, Faculty of Medicine, University of Medicine and Pharmacy Craiova
6 Department of Bacteriology-Virusology- Parasitology, Faculty of Medicine, University of Medicine and Pharmacy Craiova
7 Department of Urology, Faculty of Medicine, University of Medicine and Pharmacy Craiova
Corresponding author: [email protected]
Accepted 28 March 2026
Available Online 15 March 2016
Abstract
TO ESTABLISH THE RISK OF TUMORAL RECURRENCE FOR NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) DEPENDING ON HISTOLOGICAL OR ENVIRONMENTAL FACTORS. THE AIM OF THIS PAPER IS TO IMPROVE THE STANDARD CLINICAL CARE IN NMIBC PATIENTS FOLLOW -UP.WE INITIALLY EVALUATE D 987 PATIENTS DIAGNOSED WITH BLADDER CANCER BETWEEN JANUARY 2005 AND DECEMBER 2014. MUSCLE-INVASIVE BLADDER CAN CER (MIBC) WAS DIAGNOSED FOR 309 PATIENTS (31.3%) WHILE 678 (68.7%) HAD NMBIC. A TOTAL OF 540 PATIENTS WITH NMIBC WERE ANALYZED IN THE STUDY, WHILE THE OTHER 138 (20.4%) WERE EXCLUDED DUE TO INCOMPLETE CLINICAL DATA OR FOLLOW-UP. THE RETROSPECTIVE STUDY ANALYZED PATIENTS ’ CHARTS, DISCHARGE NOTES , ONCOLOGY REPORTS . PATIENTS WIT H AT LEAST 3 YEARS COMPLETE FOLLOW-UP DATA WERE ENROLLE D.THE AVERAGE AGE OF DI AGNOSED PATIENTS WIT H NMIBC WAS 65.3 YEARS. THE MAJORITY OF PATIENTS WERE DIAGNOSED WITH SINGLE TUMORS (68.5%). NMIBC WAS PREDOMINANT IN MALES, WITH A SEX RATIO 3.25:1 FOR MALES. BLADDER TRIGON IS THE MAIN LOCATION FOR BLADDER TUMORS. SMOKING WAS THE MAIN RISK FACTOR ACCORDING TO OUR RESULTS. SMOKERS HAD A 4 TIMES HIGHER RISK FOR NMIBC DEVELOPMENT. PATIENTS WITH MULTIPLE BLADDER TUM ORS HAD 2.28 HIGHER RISK OF RECU RRENCE. OVERALL R ECURRENCE FOR NMIBC WAS 49.1%.SMOKING IS THE MOST IMPORTANT RISK FACTOR AND THE RECURRENCE RATE IS HIGHER IN SMOKING-PATIENTS.ALSO, PATIENTS WITH MULTIPLE TUMOURS HAVE BEEN DIAGNOSED WITH HIGHER RISK FOR TUMOR RECURRENCE (P<0.05). LARGE TUMORS AND PATIENTS WITH ASSOCIATED URO LOGICAL CONDITIONS H AVE HIGHER RISK OF T UMORAL RECURRENCE (OR =2.2).
Keywords
RECURRENCE BLADDER CANCER PROGRESSION RISK FACTORS
Full Text
The body of this article is intentionally hidden on the public page. Please use the PDF reader or the PDF download for the complete text.
References
[1]
Boring CC, Squires TS, Tong T. Cancer statistics 1995. Cancer J Clin, 1995;45:2.
[2]
EAU-European association of urology guidelines 2013
[3]
Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 2009;27:295–300.
[4]
Boring CC, Squires TS, Tong T. Cancer statistics 1995. Cancer J Clin, 1995;45:2.
[5]
EAU-European association of urology guidelines 2013
[6]
Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 2009;27:295–300.
[7]
Tomescu P,Dragoescu P,Panus A,Mitroi G . Photodynamic Diagnosis of Non-Muscle Invasive Bladder Cancer Using Hexaminolevulinic Acid
[8]
Jakub D. , Siamak Daneshmand , Margit Fisch , Yair Lotan , Aidan P. Noon , Matthew J. Resnick , Shahrokh F. Shariat , Alexandre R. Zlotta and Stephen A. Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. Boorjian, European Urology, Volume 69 Issue 2, February 2016, 300-310
[9]
Sylvester RJ. How well can you actually predict which non-muscleinvasive bladder cancer patients will progress? Eur Urol 2011; 60:431–3, discussion 433 –4.Simone G, Gallucci M. Multimodality treatment versus radical cystectomy bladder sparing at cost of life? Eur Urol 2012;61:712–3.
[10]
Letašiová S, Medve'ová A, Šovčíková A, Dušinská M, Volkovová K, Mosoiu C, Bartonová A. Environ Health. Bladder cancer, a review of the environmental risk factors.2012 Jun 28;11 Suppl 1:S11
[11]
Drăgoescu O., Tomescu P., Stoica L., Pănuș A., Maria C., Bădulescu F. Tratamentul adjuvant al tumorilor vezicale non-invazive cu risc intermediar operate. Craiova Medicală 10(2):82-85, 2008.
[12]
Gluck G., Drăgoescu O., Sinescu I . Supravieţuirea pacienţilor cu cancer al vezicii urinare (No comparativ cu N+) trataţi prin cistectomie radicală. Rev Rom Urol 5(1), 2006.
[13]
Tomescu P, Pănuş A. Urologie. Ed. Medicală Universitară Craiova, 2006
[14]
Van Roekel EH, Cheng KK, James ND, et al . Smoking is associated with lower age, higher grade, higher stage, and larger size of malignant bladder tumours at diagnosis. Int J Cancer 2013;133:446 –54.